BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

Vemurafenib and dabrafenib selectively inhibit the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase, resulting in high response rates and increased survival in melanoma. Approximately 22% of individuals treated with vemurafenib develop cutaneous squamous cell carcinoma (cSCC) during ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Vin, Harina, Ojeda, Sandra S, Ching, Grace, Leung, Marco L, Chitsazzadeh, Vida, Dwyer, David W, Adelmann, Charles H, Restrepo, Monica, Richards, Kristen N, Stewart, Larissa R, Du, Lili, Ferguson, Scarlett B, Chakravarti, Deepavali, Ehrenreiter, Karin, Baccarini, Manuela, Ruggieri, Rosamaria, Curry, Jonathan L, Kim, Kevin B, Ciurea, Ana M, Duvic, Madeleine, Prieto, Victor G, Ullrich, Stephen E, Dalby, Kevin N, Flores, Elsa R, Tsai, Kenneth Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2013
Materias:
Human Biology and Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814616/
https://www.ncbi.nlm.nih.gov/pubmed/24192036
http://dx.doi.org/10.7554/eLife.00969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814616/
https://www.ncbi.nlm.nih.gov/pubmed/24192036
http://dx.doi.org/10.7554/eLife.00969

Ejemplares similares